Cytosorbents (CTSO) Net Cash Flow (2010 - 2026)

Cytosorbents' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• Quarterly Net Cash Flow fell 136.41% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.0 million (down 359.99% YoY) and the FY2025 annual result came in at -$3.5 million, up 39.59% from the prior year.
• Net Cash Flow was -$1.2 million for Q1 2026 at Cytosorbents, up from -$2.6 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $5.7 million in Q4 2023 and bottomed at -$12.7 million in Q2 2022.
• A 5-year average of -$2.8 million and a median of -$2.6 million in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow plunged 340.15% — and 2023, when it jumped 1137.17%.
• Cytosorbents' Net Cash Flow stood at -$546406.0 in 2022, then soared by 1137.17% to $5.7 million in 2023, then sank by 140.55% to -$2.3 million in 2024, then fell by 14.8% to -$2.6 million in 2025, then jumped by 54.21% to -$1.2 million in 2026.
• Business Quant data shows CTSO's Net Cash Flow at -$1.2 million in Q1 2026, -$2.6 million in Q4 2025, and -$2.5 million in Q3 2025.